BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Inebilizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Inebilizumab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05549258-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270413
DTEND;VALUE=DATE:20270414
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT05549258)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: Study of Inebilizumab in Pediat
 ric Subjects With Neuromyelitis Optica Spectrum Disorder\nEstimated primar
 y completion: 13 April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05549258
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132398-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07132398)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: Slow vs. Rapid Glucocorticoids 
 Tapering With Inebilizumab in NMOSD\nEstimated primary completion: 31 Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 32398
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06180278-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Inebilizumab: Phase 4 readout est. (NCT06180278)
DESCRIPTION:Inebilizumab\, phase 4.\nStudy: Long-term\, Open-label\, Safety
  Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)\n
 Estimated primary completion: 26 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06180278
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570798-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280806
DTEND;VALUE=DATE:20280807
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06570798)
DESCRIPTION:Inebilizumab\, phase 2\, Systemic Lupus Erythematosus.\nStudy: 
 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoi
 mmune Diseases\nEstimated primary completion: 6 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06570798
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04372615-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT04372615)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: The ExTINGUISH Trial of Inebili
 zumab in NMDAR Encephalitis\nEstimated primary completion: 30 September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04372615
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862075-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Inebilizumab: Phase 4 readout est. (NCT07862075)
DESCRIPTION:Inebilizumab\, phase 4.\nStudy: Inebilizumab for the Treatment 
 of Patients With Type 1 Autoimmune Pancreatitis\nEstimated primary complet
 ion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07862075
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724834-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT07724834)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: CD19-B Cell Depletion in PAIS-M
 E/CFS Patients\nEstimated primary completion: 1 February 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07724834
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010302-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Inebilizumab: Phase 4 readout est. (NCT07010302)
DESCRIPTION:Inebilizumab\, phase 4.\nStudy: Rituximab Versus Ravulizumab\, 
 Inebilizumab\, Satralizumab\, and Eculizumab in NMOSD\nEstimated primary c
 ompletion: January 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07010302
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987539-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300313
DTEND;VALUE=DATE:20300314
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06987539)
DESCRIPTION:Inebilizumab\, phase 2\, Generalized Myasthenia Gravis.\nStudy:
  A Study to Evaluate the Pharmacokinetics\, Pharmacodynamics\, Safety and 
 Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravi
 s (gMG)\nEstimated primary completion: 13 March 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06987539
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222553-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20310610
DTEND;VALUE=DATE:20310611
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT07222553)
DESCRIPTION:Inebilizumab\, phase 2.\nStudy: Study to Evaluate the Pharmacok
 inetics\, Pharmacodynamics\, Safety\, and Tolerability of Inebilizumab in 
 Pediatric Participants With IgG4-RD\nEstimated primary completion: 10 June
  2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07222
 553
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598825-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07598825)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: A Trial of Inebilizumab in Part
 icipants With Autoimmune Hepatitis\nEstimated primary completion: 30 July 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/inebilizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075988
 25
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07851220-5632@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20310927
DTEND;VALUE=DATE:20310928
SUMMARY:Inebilizumab: Phase 3 readout est. (NCT07851220)
DESCRIPTION:Inebilizumab\, phase 3.\nStudy: A Phase 3 Study of Inebilizumab
  in Participants With Primary Membranous Nephropathy\nEstimated primary co
 mpletion: 27 September 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/inebilizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07851220
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
